Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.

ABSTRACT:

Background

The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is unclear.

Methods

We conducted a systematic review until 1 November 2022 searching for randomized controlled trials (RCTs) involving COVID-19 patients comparing molnupiravir [±standard of care (SoC)] versus SoC and/or placebo. Data were pooled in random-effects meta-analyses. Certainty of evidence was assessed according to the Grading of Recommendations, Assessment, Development and Evaluations approach.

Results

Nine RCTs were identified, eight investigated outpatients (29 254 participants) and one inpatients (304 participants). Compared with placebo/SoC, molnupiravir does not reduce mortality [risk ratio (RR) 0.27, 95% CI 0.07-1.02, high-certainty evidence] and probably does not re

SUBMITTER: Malin JJ 

PROVIDER: S-EPMC10320168 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature